Who makes Fluad and PPV23 on the same arm?

Fluad and PPV23 on the same arm is developed by Korea University Guro Hospital.

What development phase is Fluad and PPV23 on the same arm in?

Fluad and PPV23 on the same arm is FDA-approved (marketed).

Last reviewed 2026-04-20 · How we verify

Fluad and PPV23 on the same arm

Korea University Guro Hospital · FDA-approved active Biologic Quality 2/100

Fluad and PPV23, administered together on the same arm, are marketed vaccines developed by Korea University Guro Hospital, with a key composition patent expiring in 2028. The combination's key strength lies in its dual protection against influenza and pneumococcal disease, addressing a significant unmet need in the market. The primary risk is the potential for increased competition as the key patent expires in 2028.

At a glance

Generic name	Fluad and PPV23 on the same arm
Sponsor	Korea University Guro Hospital
Modality	Biologic
Phase	FDA-approved

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

MF59-adjuvanted Influenza Vaccine and 23-valent Pneumococcal Polysaccharide Vaccine (PHASE4)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Fluad and PPV23 on the same arm CI brief — competitive landscape report
Fluad and PPV23 on the same arm updates RSS · CI watch RSS
Korea University Guro Hospital portfolio CI